Organ Transplants

Today, organ transplantation is restricted to highly-matched donors, leading to long wait times for a matching organs. Once a matching donor has been identified and the transplant is performed, recipients must begin a life-long regimen of immune system repression in order to keep the body from rejecting the transplanted organ. The drugs utilized in this regimen reduce the ability to fight disease and infection and contribute to reduced quality of life and ultimately, reduced lifespan.

Cell Source’s Veto Cell therapies aim to deliver partially mismatched donor transplants which greatly broaden the donor pool (thus avoiding the need for long waiting lists) and eliminate the need for post-transplant anti-rejection therapy, and all in the safer transplant setting that Veto Cells deliver.

Cell Source is planning to conduct clinical trials of Veto Cell-improved kidney transplants at MD Anderson.

More than 100,000 people are currently on a waiting list to receive a donor organ in the United States alone. 20 people die every day waiting for an organ transplant. Of the 39,718 transplantations performed in 2019, over 23,000 were kidney transplants (Cell Source’s initial focus for clinical trials).

According to BBC Research, the global transplantation market size was estimated at US$89.9 billion in 2020. Cell Source’s Veto Cell-facilitated organ transplantation could potentially broaden the pool of available donors while delivering increased safety and positive overall patient outcomes and longevity.